News: Articles and Publications

Qualification of a high-throughput luminescence-based serum bactericidal activity assay to assess the functionality of human sera against five Shigella serotypes

August 13, 2026•Vaccine

The role of interferon-gamma release assays in tuberculosis vaccine trials: strengths, limitations, and implications beyond trial design

August 13, 2026•Vaccine

Associations Between QuantiFERON-TB Gold Plus IFNγ Concentrations and Progression to Symptomatic Tuberculosis in Global High-Burden TB Settings

July 24, 2026•Open Forum Infectious Diseases

Gates Medical Research Institute and the Serum Institute of India Reach Agreement for the Manufacture of M72/AS01E Tuberculosis Vaccine Candidate, Pending Successful Phase 3 Outcomes

July 16, 2026•Press Release

The Gates Medical Research Institute (Gates MRI) has reached a milestone agreement with the Serum Institute of India Private Limited (SII) to manufacture M72/AS01E, a novel tuberculosis (TB) vaccine candidate.

Gates MRI and IQVIA Partner to Advance R&D in Low- And Middle-Income Countries

June 25, 2026•Press Release

The Gates Medical Research Institute (Gates MRI) has entered into an expanded, strategic collaboration with IQVIA, a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, to streamline trial operations and accelerate its clinical portfolio.

Charles Wells, MD, Appointed Chief Medical Officer and Head of Medical Development at Gates MRI

May 20, 2026•Press Release

The Gates Medical Research Institute (MRI) today announced the appointment of Charles Wells, MD, as Chief Medical Officer (CMO) and Head of Medical Development, effective May 15, 2026.

Design and feasibility considerations for a Phase 3 efficacy trial of the M72/AS01E-4 tuberculosis vaccine

May 12, 2026•Vaccine

Building and managing a complex drug discovery consortium: insights from the tuberculosis drug accelerator

April 30, 2026•Drug Discovery Today

Impact of Bifidobacterium infantis supplementation on growth, health outcomes, and gut microbiome features in underweight infants from Pakistan

April 28, 2026•Frontiers in Nutrition

A mixed-method study to inform the development of long-acting injectable TB treatments

April 14, 2026•IJTLD CRD

Interferon-gamma release assay positivity in populations at high risk of TB infection

April 14, 2026•IJTLD CRD

Krishnan Ramanathan, PhD, Appointed as Interim Chief Executive Officer of Gates Medical Research Institute

April 1, 2026•Press Release

Krishnan (Krish) Ramanathan, who has served as Chief of Staff and Head of Development at Gates Medical Research Institute (MRI), has been named Interim Chief Executive Officer (CEO) of the organization.

Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis

January 13, 2026•Nature Medicine

Bifidobacterium longum subsp. infantis and Lacticaseibacillus rhamnosus GG protect intestinal epithelium against inflammation-mediated damage in an immunocompetent in-vitro model

October 13, 2025•MDPI

CMC For Long-Acting Injectables For TB

October 3, 2025•Drug Delivery Leader